|
Cell Selection for Bone Marrow Transplants to Prevent Graft-Versus-Host-Disease Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for qualified medical advice, visits or professional assistance by using a real mD. We are not docs. Always confer with your physician about Cell Selection for Bone Marrow Transplants to Prevent Graft-Versus-Host-Disease conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Cell Selection for Bone Marrow Transplants to Prevent Graft-Versus-Host-Disease Clinical research trials and Cell Selection for Bone Marrow Transplants to Prevent Graft-Versus-Host-Disease health trials occur in many of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectivity of new does drugs. The intent of the studies / undertakings is to resolve particular human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to detect remedies for all sorts of conditions, including Cell Selection for Bone Marrow Transplants to Prevent Graft-Versus-Host-Disease. Cell Selection for Bone Marrow Transplants to Prevent Graft-Versus-Host-Disease Clinical Trials and other clinical trials permit volunteers to obtain healthcare treatment alternatives before they are available to the masses. Most times the participants undergo professional assistance for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Cell Selection for Bone Marrow Transplants to Prevent Graft-Versus-Host-Disease clinical trial. Test subjects typically receive the most expert healthcare available for their Cell Selection for Bone Marrow Transplants to Prevent Graft-Versus-Host-Disease condition. Dangers are a reality, however, and may include more or frequent mD visits, healthcare dangers (perhaps life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Cell Selection for Bone Marrow Transplants to Prevent Graft-Versus-Host-Disease  Cell Selection for Bone Marrow Transplants to Prevent Graft-Versus-Host-Disease
Cell Selection for Bone Marrow Transplants to Prevent Graft-Versus-Host-Disease
For Condition: Graft vs Host Disease,Hematologic Neoplasm
Status: Recruiting
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: Blood contains different kinds of cells, white blood cells, red blood cells, and platelets. In order to treat certain diseases, specific cell types can be removed from blood and transplanted into patients. The process of removing white blood cells for the treatment of leukemia is called apheresis. This study will make available blood cell collections from volunteers genetically matched to various degrees with recipients in order to test and, if necessary, refine the process of removing white blood cell T-lymphocytes.
Details: This protocol has been written to make available apheresis collections from volunteers matched to various degrees with recipients in order to test and, if necessary refine, the selective immunodepletion procedure prior to introducing it in a clinical trial.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: Family members of patients admitted to NHLBI allogeneic BMT protocols for hematological malignancy or solid tumors . Age 18-65 . HLA type is determined in the course of searching for a donor, or parent of patient (obligate haplotype match) will be included. HLA 3/6, 4/6, 5/6, 6/6 match with patient will be included. Research apheresis must be available from patient. Venous access suitable for apheresis using antecubital veins. Signed consent . EXCLUSION CRITERIA: Less than 18 or greater than 65. Pregnancy or lactation. HLA type unknown. III Volunteer not a parent of patient. More than one haplotype mismatch with patient . Venous access inadequate. Research apheresis available from patient.
Total Enrollment: 20
Location and Contact Information:
National Heart, Lung and Blood Institute (NHLBI) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting Patient and Public Liaison Office 1-800-411-1222
Additional Information:
Study ID Numbers: 990037; 99-H-0037
Study Start Date: February 2, 1999
Record last reviewed: February 9, 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001872
Other Graft Vs Host Disease Studies:
1. Stem Cell (Modified Bone Marrow) Transplantation in HIV-Infected Patients with Blood Cancer
2. Screening for Hematology Branch Protocols
3. Bone Marrow Transplant Studies for Safe and Effective Treatment of Leukemia
4. The Collection of Peripheral Blood Lymphocytes and Marrow Progenitor Cells from Normal Volunteers and Volunteers with Lymphoid or Hematologic Malignancies
5. Evaluation, Treatment, and Training for Patients with Blood Disorders
Related Studies:
Other Graft vs Host Disease Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Cell Selection for Bone Marrow Transplants to Prevent Graft-Versus-Host-Disease
|
|
|
|
|
|
|
|
